New Vulnerabilities in MYC-Driven Breast Cancer
New Vulnerabilities in MYC-Driven Breast Cancer
批准号:
10333228
负责人:
Thomas Westbrook
金额:
$53.8万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-05 至 2023-05-31
关键词:
Animal ModelAnimalsAntiviral ResponseApoptosisApoptoticBiologicalBreast Cancer CellBreast Cancer PatientCancer PatientCell DeathCellular StressClinicClinical TrialsDNA DamageDataDefectDiagnosisDouble-Stranded RNAEvaluationGene ExpressionGenesGeneticGenetic EngineeringGenetic ScreeningGenetic TranscriptionGenomeGenomicsHumanImmune signalingImpairmentInnate Immune SystemIntronsLinkMYC geneMalignant NeoplasmsMessenger RNAMethodsMicroscopyMolecularNatureOncogenesOncogenicPathway interactionsPatient CarePatient-derived xenograft models of breast cancerPharmacologyPre-Clinical ModelProcessPrognosisProteinsProteomeProteomicsProto-Oncogene Proteins c-mycRNARNA FoldingRNA InterferenceRNA SplicingRNA interference screenRNA metabolismResearchRoleScienceShapesSignal PathwaySignal TransductionSourceSpliceosomesStressStructureTherapeuticWorkbiological adaptation to stressbreast cancer survivalcancer cellcancer typecell behaviorcohortcombatforward geneticsgene discoverygene networkgenetic inhibitorin vivoinhibitorinnate immune pathwaysinsightmRNA Precursormalignant breast neoplasmneoplastic cellnext generation sequencingnovelnovel therapeuticspathogenic viruspatient derived xenograft modelrefractory cancerresponsesensorsingle moleculesmall moleculetargeted treatmenttranscription factortranscriptometranscriptome sequencingtriple-negative invasive breast carcinomatumor progressiontumorigenesiswhole genome
中文摘要
三阴性乳腺癌(TNBC)是一种具有侵袭性的乳腺癌亚型
英文摘要
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with more than
200,000 new diagnoses each year. The oncogene Myc is a common driver of TNBC. However, despite
important research into the biologic and molecular functions of Myc, no tractable therapies have emerged to
inhibit this oncogenic transcription factor. TNBC and other Myc-driven cancers remain recalcitrant to current
targeted therapies, underlining the urgent need to identify new vulnerabilities in these malignancies.
In addition to promoting tumorigenesis, oncogenes such as Myc also produce unique stresses in
cancer cells, collectively termed oncogenic stress. Using parallel whole-genome RNAi screens, we discovered
that Myc imposes a new type of oncogenic stress on TNBCs that we term RNA splicing stress, or RSS
(Kessler, Science 2012; Hsu, Nature 2015). In many cancer types, Myc (or other oncogenic insults) globally
amplifies transcription leading to increased pre-mRNA burden on the spliceosome. Consequently, Myc-driven
TNBCs are exquisitely sensitive to modest perturbations in the spliceosome (by enhancing RSS). Importantly,
pharmacologic or genetic inhibitors of the spliceosome impair primary and metastatic progression of TNBC and
are well tolerated in animal pre-clinical models. While spliceosome inhibitors have entered clinical trials, the
mechanisms by which RSS and spliceosome inhibitors selectively kill cancer cells are unknown. Herein, we
propose to discover the pathway(s) sensing and responding to RNA splicing stress and to delineate the
mechanisms by which RSS triggers cancer cell death.
Aim 1: Delineate the dsRNA-sensing pathways (DSP’s) stimulated by RSS in Myc+ TNBCs in vivo. Our
preliminary data suggest that RSS induces TNBC apoptosis by triggering innate immune pathways that detect
and respond to dsRNAs. By leveraging a TNBC PDX cohort with new genetic and proteomic platforms, we will
determine how DSP’s and other stress response pathways are activated in response to spliceosome inhibition.
Aim 2: Discover how RSS triggers dsRNA-sensing pathways in TNBCs. Many viral pathogens encode
dsRNA genomes that are detected by dsRNA-sensors of the innate immune system. Our studies indicate
RSS leads to cytoplasmic accumulation of intron-retained mRNAs, a potential source of dsRNAs. Using new
sequencing and single-molecule microscopy methods, we will study the mechanisms by which RSS shapes
the secondary structure and subcellular localization of TNBC transcriptomes and stimulates dsRNA-sensors.
Aim 3: Delineate how DSPs and other stress response pathways govern TNBC response to
spliceosome inhibitors. We hypothesize that there is a coordinated cellular response to RSS that parallels
well-studied homeostatic stress responses like the unfolded protein response. By leveraging forward genetics
and identifying new regulators of RSS, we propose to unveil a genetic framework for this novel type of cellular
stress and provide new therapeutic inroads that exploit this cancer vulnerability.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic Targeting of RNA Splicing in Triple-Negative Breast Cancer
-
批准号:10660649
-
项目类别:
-
资助金额:$71.73万
-
财政年份:2018
-
负责人:Thomas Westbrook
-
依托单位:
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
-
批准号:9891027
-
项目类别:
-
资助金额:$38.23万
-
财政年份:2017
-
负责人:Thomas Westbrook
-
依托单位:
Project 2: Targeting RTK Co-Dependencies in Triple-Negative Breast Cancer
-
批准号:10219970
-
项目类别:
-
资助金额:$33.52万
-
财政年份:2014
-
负责人:Thomas Westbrook
-
依托单位:
Project 2: Targeting RTK Co-Dependencies in Triple-Negative Breast Cancer
-
批准号:10460215
-
项目类别:
-
资助金额:$33.71万
-
财政年份:2014
-
负责人:Thomas Westbrook
-
依托单位:
Project 2: Targeting RTK Co-Dependencies in Triple-Negative Breast Cancer
-
批准号:10704539
-
项目类别:
-
资助金额:$33.18万
-
财政年份:2014
-
负责人:Thomas Westbrook
-
依托单位:
Discovering genetic networks of triple-negative breast cancer
-
批准号:8685919
-
项目类别:
-
资助金额:$31.5万
-
财政年份:2013
-
负责人:Thomas Westbrook
-
依托单位:
Discovering genetic networks of triple-negative breast cancer
-
批准号:9265420
-
项目类别:
-
资助金额:$32.47万
-
财政年份:2013
-
负责人:Thomas Westbrook
-
依托单位:
Discovering genetic networks of triple-negative breast cancer
-
批准号:8560337
-
项目类别:
-
资助金额:$32.47万
-
财政年份:2013
-
负责人:Thomas Westbrook
-
依托单位:
Discovering genetic networks of triple-negative breast cancer
-
批准号:8847687
-
项目类别:
-
资助金额:$32.47万
-
财政年份:2013
-
负责人:Thomas Westbrook
-
依托单位:
Discovering genetic networks of triple-negative breast cancer
-
批准号:9040908
-
项目类别:
-
资助金额:$32.47万
-
财政年份:2013
-
负责人:Thomas Westbrook
-
依托单位:
GENOME WIDE RNAI SCREENING AND ANALYSIS
-
批准号:8180997
-
项目类别:
-
资助金额:$9.21万
-
财政年份:2010
-
负责人:Thomas Westbrook
-
依托单位:
CORE C: Genome Wide RNAi Screens
-
批准号:7759246
-
项目类别:
-
资助金额:$19.81万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
Shared Resource: Cell-Based Assay Screening Service
-
批准号:9118148
-
项目类别:
-
资助金额:$10.18万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
GENOME WIDE RNAI SCREENING AND ANALYSIS
-
批准号:8296126
-
项目类别:
-
资助金额:$8.34万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
CORE C: Genome Wide RNAi Screens
-
批准号:8382001
-
项目类别:
-
资助金额:$20.26万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
CORE C: Genome Wide RNAi Screens
-
批准号:8318645
-
项目类别:
-
资助金额:$20.19万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
GENOME WIDE RNAI SCREENING AND ANALYSIS
-
批准号:8376826
-
项目类别:
-
资助金额:$8.14万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
Shared Resource: Cell-Based Assay Screening Service
-
批准号:9759805
-
项目类别:
-
资助金额:$12.63万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
CORE C: Genome Wide RNAi Screens
-
批准号:8508977
-
项目类别:
-
资助金额:$9.6万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
Shared Resource: Cell-Based Assay Screening Service
-
批准号:8934797
-
项目类别:
-
资助金额:$12.71万
-
财政年份:--
-
负责人:Thomas Westbrook
-
依托单位:
海外基金